Skip to Content
Join the 'Head and Neck Cancer' group to help and get support from people like you.

Head and Neck Cancer News

Related terms: Oral Cancer

Blood Test Might Spot Cancer Years Earlier

THURSDAY, July 23, 2020 – Scientists are working on a blood test that may catch five common cancers years sooner than current methods. The blood test, which is still experimental, hunts for certain...

Keep Flossing: Study Ties Gum Disease to Higher Cancer Risk

TUESDAY, July 21, 2020 – Want to avoid cancer? Consider brushing and flossing more often. Why? Folks with bad gums might be at higher risk of developing certain types of cancer, new research...

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer

TUESDAY, July 21, 2020 – Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma, according to a research letter...

FDA Approves Merck’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers

KENILWORTH, N.J.--(BUSINESS WIRE) June 12, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma

KENILWORTH, N.J.--(BUSINESS WIRE) June 11, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...

Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...

Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer

PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2016 --Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab)...

FDA Approves Merck’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...

Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula

San Jose, Calif. - December 28, 2015 - Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel...

FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer

SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage...

Ask a Question

Want to post your own question to this support group? You'll need to first create an account with Drugs.com (or sign in to your existing account).

Further Information

Related Condition Support Groups

Cancer

Related Drug Support Groups

methotrexate, Keytruda